Pharmaceutical

NMPA approves Astellas’ PADCEV for advanced urothelial cancer

China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved Astellas’ PADCEV (enfortumab vedotin).

Aug 21, 2024 - 04:00
NMPA approves Astellas’ PADCEV for advanced urothelial cancer
China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved Astellas’ PADCEV (enfortumab vedotin).
Read the original article

Tags:

Previous Article

Colombia’s president signs law to strengthen pharmaceutical sector

Next Article

Homemade Hair Growth Shampoo

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Dana-Farber executive says split from Mass General will benefit patients

STAT+: Dana-Farber executive says split from Mass Gener...

Oct 18, 2023

Biden shakes up US drug pricing landscape with inflation-related penalties 

Biden shakes up US drug pricing landscape with inflatio...

Dec 16, 2023

A chatbot that’s cautious about GPT, AI pronouncements, and a VC looks to Israel

A chatbot that’s cautious about GPT, AI pronouncements,...

Jun 16, 2023